These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 15711315

  • 1. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
    Paick SH, Meehan A, Lee M, Penson DF, Wessells H.
    J Urol; 2005 Mar; 173(3):903-7. PubMed ID: 15711315
    [Abstract] [Full Text] [Related]

  • 2. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [Abstract] [Full Text] [Related]

  • 3. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F, CombAT Study Group.
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [Abstract] [Full Text] [Related]

  • 4. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
    Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA.
    BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
    [Abstract] [Full Text] [Related]

  • 5. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.
    Paranhos M, Antunes A, Andrade E, Freire G, Srougi M.
    BJU Int; 2009 Oct; 104(8):1130-3. PubMed ID: 19426190
    [Abstract] [Full Text] [Related]

  • 6. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L.
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [Abstract] [Full Text] [Related]

  • 7. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS.
    N Engl J Med; 1992 Oct 22; 327(17):1185-91. PubMed ID: 1383816
    [Abstract] [Full Text] [Related]

  • 8. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S, Cesaretti J, Stone NN, Stock RG.
    BJU Int; 2006 Nov 22; 98(5):979-81. PubMed ID: 17034599
    [Abstract] [Full Text] [Related]

  • 9. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T, Masumori N, Rahman M, Crane MM.
    Int J Urol; 2007 Apr 22; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [Abstract] [Full Text] [Related]

  • 10. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
    Antunes AA, Srougi M, Dall'oglio MF, Vicentini F, Paranhos M, Freire GC.
    J Sex Med; 2008 Jul 22; 5(7):1702-7. PubMed ID: 18194186
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J.
    N Engl J Med; 1998 Feb 26; 338(9):557-63. PubMed ID: 9475762
    [Abstract] [Full Text] [Related]

  • 13. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.
    Ikuerowo SO, Akindiji YO, Akinoso OA, Akinlusi FM, Esho JO.
    Urol Int; 2008 Feb 26; 80(3):296-9. PubMed ID: 18480635
    [Abstract] [Full Text] [Related]

  • 14. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate.
    Volkan T, Ihsan TA, Yilmaz O, Emin O, Selcuk S, Koray K, Bedi O.
    Eur Urol; 2005 Oct 26; 48(4):608-13. PubMed ID: 16135396
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL.
    J Urol; 2009 Feb 26; 181(2):710-6. PubMed ID: 19091352
    [Abstract] [Full Text] [Related]

  • 18. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS.
    J Urol; 2007 Apr 26; 177(4):1401-7. PubMed ID: 17382741
    [Abstract] [Full Text] [Related]

  • 19. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z.
    Urology; 2008 Nov 26; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.